The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
They made it across a deadly sea this year, but their journey to what they hope will be political asylum had only just begun.
Scientists used modern forensic techniques to review the 'cold case' and determine the victim was probably killed by two blows to the head.
US computer science expert says "endpoint" of lethal drone technology is killer robots that choose targets via artificial intelligence.